Synthetic Bio Firm GeneForge Files for Chapter 7 Bankruptcy | GenomeWeb

NEW YORK (GenomeWeb News) – Synthetic biology instrument firm GeneForge has declared Chapter 7 bankruptcy and will be liquidating its assets.

The firm filed its petition on Dec. 7 in US Bankruptcy Court, Western District of Washington, listing $435,541 in assets and $2.5 million in liabilities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.